Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic...

Area of Science:

• Oncology
• Immunotherapy
• Biomarkers

Background:

• The prognostic value of the lung immune prognostic index (LIPI) is established in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).
• However, its utility in a broader pancancer setting remains to be fully elucidated.

Approach:

• A comprehensive systematic literature search was performed across major databases (PubMed, Embase, Web of Science, Cochrane Library) up to July 2023.
• Meta-analysis of 35 studies, including 9959 patients, evaluated the association between LIPI scores and clinical outcomes (OS, PFS, ORR, DCR) in patients receiving ICIs.
• Patients were stratified into LIPI groups (good, intermediate, poor) for comparative analysis.

Key Points:

• A higher LIPI score was significantly associated with worse overall survival (OS) across all comparisons (HRs ranging from 1.69 to 3.03).
• Elevated LIPI scores correlated with shorter progression-free survival (PFS) (HRs ranging from 1.41 to 2.23).
• Increased LIPI scores were linked to lower objective response rates (ORR) and disease control rates (DCR).

Conclusions:

• The lung immune prognostic index (LIPI) demonstrates robust prognostic capability in stratifying clinical outcomes for patients with NSCLC and other solid tumors treated with ICIs.
• LIPI serves as a cost-effective, simple, and accurate prognostic tool applicable in a pancancer context.
• This index can aid in the risk stratification of patients undergoing immunotherapy.